EU approves AstraZeneca's Tagrisso with addition of chemotherapy as new 1st─line treatment for patients with EGFR─...
AstraZeneca’s Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been approved in the European Union (EU) for the 1st-line treatment of adult patients with advanced epidermal growth factor receptor-mutated (EGFRm) …